trending Market Intelligence /marketintelligence/en/news-insights/trending/StCVeC4AMHAE_4DtC5X0Tg2 content esgSubNav
In This List

Approval for Astrazeneca, Merck & Co.; designation for Savara

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Approval for Astrazeneca, Merck & Co.; designation for Savara

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 3.

Approvals

* AstraZeneca PLC and Merck & Co. Inc.'s Lynparza as a stand-alone maintenance therapy for BRCA-mutated pancreatic cancer that has spread but has not progressed for at least 16 weeks following first-line platinum-based chemotherapy.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: AP Photo

Breakthrough therapy

* Savara Inc.'s Molgradex for autoimmune pulmonary alveolar proteinosis.